Drug Information Association Logo

EMA's Guido Rasi to Speak at DIA EuroMeeting 2013

Basel, Switzerland — Feb 4, 2013

Guido Rasi, head of the European Medicines Agency (EMA), is just one of the many A-list participants set to speak at DIA Europe’s 25th Annual EuroMeeting in Amsterdam from 4-6 March, 2013.

Professor Rasi, Executive Director of the EMA, joins more than 300 speakers, moderators and panelists from around the world, who substantiate the meeting’s claim to being the most important event in the medicines development calendar. He will co-chair the event’s Regulatory Town Hall Meeting on 6 March, together with Christa Wirthumer-Hoche, Member of the Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), and Deputy Head, Austrian Medicines and Medical Devices Agency (AGES). This session will give attendees the chance to ask burning questions to experts about a broad range of current hot topics in the development of medicines.

Other high-profile EuroMeeting 2013 participants include:

  • Andrzej Rys, Director in Directorate C, Public Health and Risk Assessment, Directorate General for Health and Consumer Affairs (DG SANCO)
  • Tomas Salmonson, Chair Committee for Medicinal Products for Human Use (CHMP), Senior Scientific Advisor, Medical Products Agency (MPA), Sweden
  • Hans-Georg Eichler, Senior Medical Officer, EMA, who will chair a special session on the agency’s Scientific Committees
  • June Raine, Director of Vigilance and Risk Management of Medicines, Medicines and Health Care Products Regulatory Agency (MHRA), UK
  • Dr. Stephen Spielberg, M.D., Ph.D., Editor-in-Chief of DIA’s peer-reviewed scientific journal, Therapeutic Innovation & Regulatory Science (TIRS)

As a neutral global forum the EuroMeeting 2013 will feature more than 110 sessions, 200 exhibitors and bring together professionals from the biopharmaceutical industry, contract research and service organizations, academic research centers, health ministries and delegates from ptient organizations to share knowledge focusing on better public health protection, greater transparency of processes and the rational use of medicinal products. Among the packed conference programme professionals will have the opportunity to discuss current issues with fellow colleagues and the expert presenters.

Programme co-chair Beatriz Vicén Banzo, Head of Public Affairs and Technical Department in Bayer Spain, said: “The proposed areas for discussion for the EuroMeeting 2013 are classified into general disciplines including pharmacovigilance and regulatory affairs for medicinal products and medical devices, research and development, and clinical trials. The scope of the presentations will cover the experience gathered after the implementation of the new pharmacovigilance legislative framework.”

The Pharmacovigilance Directive, which has applied in the EU since July 2012, sets out new legislation and guidance for the continuous monitoring of a medicines’ safety and actions to reduce risks and increase the benefits of medicines.

Programme co-chair Peter Bachmann, Chair of CMDh, added: “Knowing what still needs to be done – or improved – and most importantly: ‘are we getting what was initially expected from the Pharmacovigilance Directive?’. These are some of the key areas that the professionals attending the meeting will be able to learn about and debate. Other important topics include the Falsified Medicines and Information to Patients directives and considerations over an ageing population and the potential impact on hospitalizations.”

For more information about the event visit www.diahome.org/EM2013.







ABOUT DIA: DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators and influencers to exchange knowledge and collaborate in an impartial setting. DIA’s network creates unparalleled opportunities for the exchange of knowledge and has the interdisciplinary experience to prepare for future developments. The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients. DIA is an independent, nonprofit organization with its global center in Washington, D.C., USA; regional offices covering North and South America (Horsham, Penn., USA); Europe, North Africa and the Middle East (Basel, Switzerland); and Japan (Tokyo), India (Mumbai) and China (Beijing). For more information, visit www.diahome.org.